Kalaris Therapeutics reported encouraging additional data from its Phase 1a single-ascending-dose trial of TH103 in neovascular age-related macular degeneration. While still early-stage, the update is a positive clinical signal for the program’s development.
Kalaris Therapeutics reported encouraging additional data from its Phase 1a single-ascending-dose trial of TH103 in neovascular age-related macular degeneration. While still early-stage, the update is a positive clinical signal for the program’s development.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
